Novo Nordisk

The discussion

The sole perspective provided comes from a guest host taking a bearish stance on Novo Nordisk with low conviction. The guest, channeling RFK Jr.'s argument, contends that Novo Nordisk's valuation is almost entirely dependent on projected U.S. Ozempic sales driven by lobbying efforts to secure Medicare coverage — rather than on clinically superior outcomes. As evidence of this, the guest notes the irony that Ozempic's home country does not recommend the drug for diabetes, suggesting the business model relies on regulatory capture in the U.S. market. No other hosts weighed in, so no consensus or disagreement can be assessed from the available material.